Also found in: Medical.
HER2Human EGF (Epidermal Growth Factor) Receptor 2 (oncology)
References in periodicals archive ?
For a long time, we have been concentrating on the protein HER2 but now we have this gene that could be responsible for the spread of the cancer.
These observations have provided a strong rationale for inhibition of both EGFR and HER2 in the treatment of HER2-positive tumours and have led to the development of lapatinib, which is a small-molecule, dual tyrosine-kinase inhibitor of EGFR and HER2 currently approved for use in HER2-positive breast cancer.
HERmark provides accurate and quantitative measurements of HER2 total protein levels and HER2:HER2 homodimer levels.
The study also showed 30% of clinicians admitted HER2 status was rarely available and missing HER2 results led to extra out-patient visits in 46% of responses.
First, important clinical data presented demonstrates the superiority of HERmark over FISH testing for HER2.
In 20 to 30 percent of breast cancer eases, overproduction of HER2 stimulates cell proliferation.
The HER2 gene produces a specific protein found on a cell's surface that acts like an antenna, receiving signals to grow.
Perjeta is designed specifically to prevent the HER2 receptor from pairing (or "dimerizing") with other HER receptors (EGFR/HER1, HER3 and HER4) on the surface of cells, a process that is believed to play a role in tumor growth and survival.
These pooled data show the overall survival benefit of eribulin in the important and often forgotten about HER2 negative and triple negative subtypes, who constitute the majority of patients with cancer.
HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17.
Around 15% of breast cancers are HER2-positive, The new drug, from Roche Holding AG, attaches to the HER2 growth receptor and blocks signals that encourage the cancer to grow and spread.
In addition, FISH testing has the ability to detect aneuploidy that may reflect both an adverse overall prognosis and the likelihood of downstream HER2 protein overexpression.